|
US5294612A
(en)
*
|
1992-03-30 |
1994-03-15 |
Sterling Winthrop Inc. |
6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
|
|
GB9423911D0
(en)
*
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
|
DE19518082A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Merck Patent Gmbh |
4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
CN1281588C
(en)
|
1997-04-25 |
2006-10-25 |
美国辉瑞有限公司 |
Novel intermediate for prepn. of pyrazolopyrimidinones
|
|
GB9722520D0
(en)
|
1997-10-24 |
1997-12-24 |
Pfizer Ltd |
Compounds
|
|
US6472425B1
(en)
|
1997-10-31 |
2002-10-29 |
Nitromed, Inc. |
Methods for treating female sexual dysfunctions
|
|
CZ301911B6
(en)
*
|
1997-11-12 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
2-Phenyl-substituted imidazotriazinones, process of their preparation, medicaments containing those compounds and their use
|
|
CA2329077C
(en)
*
|
1998-04-20 |
2007-09-18 |
Pfizer Inc. |
Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
|
|
GB9823101D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9823102D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
GB9823103D0
(en)
|
1998-10-23 |
1998-12-16 |
Pfizer Ltd |
Pharmaceutically active compounds
|
|
KR100353014B1
(en)
*
|
1998-11-11 |
2002-09-18 |
동아제약 주식회사 |
Pyrazolopyrimidinone derivatives for the treatment of impotence
|
|
US6225315B1
(en)
|
1998-11-30 |
2001-05-01 |
Pfizer Inc |
Method of treating nitrate-induced tolerance
|
|
GB9910378D0
(en)
*
|
1999-05-05 |
1999-06-30 |
Smithkline Beecham Plc |
Novel compounds
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
CZ20021151A3
(en)
|
1999-10-11 |
2003-03-12 |
Pfizer Inc. |
5-(2-substituted-5-heterocyclyl sulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ones functioning as phosphodiesterase inhibitors
|
|
TWI265925B
(en)
|
1999-10-11 |
2006-11-11 |
Pfizer |
Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
|
|
US6683081B2
(en)
|
1999-12-24 |
2004-01-27 |
Bayer Aktiengesellschaft |
Triazolotriazinones and the use thereof
|
|
JP2004525857A
(en)
*
|
2000-04-19 |
2004-08-26 |
ジョンズ・ホプキンス・ユニバーシティ |
Methods for prevention and treatment of gastrointestinal disorders
|
|
KR100377782B1
(en)
*
|
2000-06-23 |
2003-03-29 |
동아제약 주식회사 |
A process for preparing pyrazolopyrimidinone derivatives for the treatment of impotence
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
DE60235198D1
(en)
|
2001-12-20 |
2010-03-11 |
Merck Serono Sa Coinsins |
PYRROLIDIN DERIVATIVES AS PROSTAGLANDIN MODULATORS
|
|
GB0202282D0
(en)
|
2002-01-31 |
2002-03-20 |
Pfizer Ltd |
Treatment of male sexual dysfunction
|
|
DE10232113A1
(en)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Medicinal products containing vardenafil hydrochloride trihydrate
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
JP4015176B2
(en)
|
2003-04-29 |
2007-11-28 |
ファイザー・インク |
5,7-Diaminopyrazolo 4,3-dipyrimidines useful for the treatment of hypertension
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
ES2317209T3
(en)
|
2004-04-07 |
2009-04-16 |
Pfizer Inc. |
PIRAZOLO (4,3-) PYRIMIDINS.
|
|
DE102005009240A1
(en)
|
2005-03-01 |
2006-09-07 |
Bayer Healthcare Ag |
Dosage forms with improved pharmacokinetic properties
|
|
AU2006245416B2
(en)
|
2005-05-12 |
2012-02-23 |
Pfizer Inc. |
Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
|
|
CN1966506A
(en)
*
|
2005-11-17 |
2007-05-23 |
上海特化医药科技有限公司 |
Pyrromonazole pyrimidinone derivatives, method of producing them and use thereof
|
|
WO2013067309A1
(en)
|
2011-11-04 |
2013-05-10 |
Xion Pharmaceutical Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|